The fully-funded doctoral initiative was jointly launched by the University of Cambridge, the Ineos Oxford Institute for AMR, and the University of Oxford.
The initiative integrates the expertise and capabilities of the two Universities, globally recognised for excellence in health science research, and it is funded by the INEOS Oxford Institute.
There are six fully-funded PhD/DPhil studentships available to start in October 2022.
The successful candidates will be fully funded for three and a half years, and whilst registered at either Oxford or Cambridge will have the opportunity to work on collaborative projects that span both universities, on opportunities such as using cutting-edge biophysics to combat drug resistance in different microbes and new genetic technologies to support the discovery of new drugs.
In this round, there are six available projects – three registered in Cambridge and three in Oxford, each with collaborations in the other University.
Importantly, for the application process, there are two steps:
- Make initial contact with the primary supervisor of the project you are interested in. Email details are shown in the project description in the provided link.
- The supervisors will provide further information about the projects and advice on how to submit a formal application to the correct course via the relevant University’s application portal.
If you have any questions about the application process, please contact Joyce Nwekwu.
More details about the programme, and list of projects, can be found on the programme website.
About the Ineos Oxford Institute (IOI):
The Ineos Oxford Institute (IOI) was founded at the University of Oxford in 2021 to combat this pressing global challenge – bringing together world-class talent to develop innovative solutions to slow and reverse the spread of drug-resistant infections.
Based at the Sir William Dunn School of Pathology, where penicillin was first developed into a viable drug, the IOI is working with the University of Oxford and the University of Cambridge to harness their combined expertise as globally recognised centres of excellence for health science research by funding six new doctoral (PhD or DPhil) places in leading antimicrobial research teams.
The shared vision of the IOI, the funder INEOS and both universities is to nurture a new generation of outstanding scientific champions that will be equipped to tackle the global challenge of drug-resistant infections.